866-997-4948(US-Canada Toll Free)

Oral Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 40 Pages


Global Markets Directs, \'Oral Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Oral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer. 

Oral Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Oral Cancer.
  • A review of the Oral Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Oral Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Oral Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Oral Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oral Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Oral Cancer 7
Oral Cancer Therapeutics under Development by Companies 9
Oral Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Oral Cancer Therapeutics - Products under Development by Companies 15
Oral Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Oral Cancer Therapeutics Development 17
NexMed, Inc. 17
Oral Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
HPPH - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Survivin-Derived Peptide Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Taxotere + Cisplatin + 5-FU - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
vesnarinone - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
curcumin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
paclitaxel - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
celecoxib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
interleukin-15 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Oral Cancer Therapeutics - Drug Profile Updates 36
Oral Cancer Therapeutics - Discontinued Products 37
Oral Cancer Therapeutics - Dormant Products 38

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Table


Number of Products Under Development for Oral Cancer, H1 2013 7
Products under Development for Oral Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
NexMed, Inc., H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Oral Cancer Therapeutics - Drug Profile Updates 36
Oral Cancer Therapeutics - Discontinued Products 37
Oral Cancer Therapeutics - Dormant Products 38

List of Chart


Number of Products under Development for Oral Cancer, H1 2013 7
Products under Development for Oral Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *